Arias PJ, Bustamante OS, Ortiz GV, Moya MM

Language: Spanish
References: 18
Page: 651-663
PDF size: 170.59 Kb.

ABSTRACT

Objective: To compare the antimicrobial activity of generic meropenem and innovative meropenem on resistant strains of clinical interest by using the microdilution technique.
Method: The minimum inhibitory concentration and maximum bactericidal concentration were determined by the microdilution according to the protocol set by the Clinical and Laboratory Standards Institute (CLSI).
Result: Minimum inhibitory concentration (MIC) of 320 µg/mL and a maximum bactericidal concentration (MBC) of 640 µg/mL for both antibiotics against Staphylococcus aureus. MIC reached 640 µg/mL and MBC of 1 280 µg/mL in both antibiotics for Escherichia coli whereas the MIC was 5 120 µg/mL and WBC of 20 480 µg /mL with both antibiotics against Klebsiella pneumoniae.
Conclusion: No significant differences were observed in minimum inhibitory concentration and maximum bactericidal concentration between generic meropenem and innovative meropenem.

REFERENCES

1. Andrews JM Determination of Minimum Inhibitory Concentration. Journal Antimicrobial Chemotherapy. 2001;48(31):5.

2. Paterson DL, Bonomo RA Extended-spectrum beta-lactamases: a clinical update. Clinical Microbiology Reviews. 2005;18:657-86.

3. Fresnadillo MJ, Garcia MI, Garcia E, Garcia JE Los carbapenems disponibles: propiedades y diferencias. Enfermedades infecciosas y microbiología clínica. 2010;28:53-64.

4. Brown SD, Traczewski MM. Comparative In Vitro Antimicrobial Activity of a New Carbapenem, Doripenem: Tentative Disc Diffusion Criteria and Quality Control. Journal of Antimicrobial Chemotherapy. 2005;55:944–9.

5. Jones RN, Huynh HK. Doripenem (S- 4661), a Novel Carbapenem: Comparative Activity against Contemporary Pathogens Including Bactericidal Action and Preliminary In Vitro Methods Evaluations. Journal of Antimicrobial Chemotherapy 2004;54(1):144–54.

6. Swabb EA. Review of the Clinical Pharmacology of the Monobactams Antibiotic Aztreonam. The American Journal of Medicine. 1985;78(2A):8–11.

7. Andrews JM Determination of Minimum Inhibitory Concentration. Journal Antimicrobial Chemotherapy. 2001;48(31):5.

8. Clinical and Laboratory Standards Institute (CLSI). Methods for dilution microbial susceptibility tests for bacteria that grow aerobically; approved standard. 7th edition M7-A7. Wayne, PA: CLSI; 2006.

9. Hacek D, Dressel D, Peterson L. Highly Reproducible Bactericidal Activity Test Results by Using a Modified National Committee for Clinical Laboratory Standards Broth Macrodilution Technique. Journal of Clinical Microbiology. 1999;37(6):1881.

10. Adachi JA, Jiang ZD, Mathewson JJ, Verenkar MP, Thompson S, Martínez SF, et al. Enteroaggregative Escherichia coli as a major etiologic agent in traveler's diarrhea in 3 regions of the world. Clin. Infect. Dis. 2001;32:1706-1709.

11. Emori TG, Gaines RP. An overview of nocosomial infections, including the role of the microbiology laboratory. Clinical Microbiology Reviews. 1993;6:428-442.

12. Espinal PA, Mantilla JR, Saavedra C, Leal AL, Alpuche C, Valenzuela EM Epidemiologia molecular de infección nocosomial por Klebsiella pneumoniae productora de b-lactamasas de espectro extendido. Biomédica. 2004;24:252-61.

13. Paterson DL, Hujer KM, Hujer AM, Yeiser B, Bonomo MD, Rice LB. Extendedspectrum beta-lactamases in Klebsiella pneumoniae bloodstream isolates from seven countries: dominance and widespread prevalence of SHV- and CTX-M-type beta-lactamases. Antimicrobial Agents and Chemotherapy. 2003;47:3554-60.

14. Hyle E, Lipworth A, Zaoutis T, Nachamkin I, Fishman N, Bilker WR. Factors for increasing multidrug resistance among extended-spectrum β‒lactamase producing Escherichia coli and Klebsiella species. Clinical Infections Diseases 2005;40:1317-1324.

15. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiology. 2007;2:501-12.

16. Tafur J, Torres J, Villegas M. Mecanismos de resistencia a los antibióticos en bacterias Gram negativas. Infectologia. 2008;12:217-226.

17. Villegas M, Lolans K, Correa A, Suarez C, Lopez JA, Vallejo M. First detection of the plasmidmediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrobial Agents and Chemotherapy 2006;50:2880-2882.

18. Poirel L, Pitout JD, Nordmann P. Carbapenemases: molecular diversity and clinical consequences. Future Microbiology. 2007;2:501-12.